TAHO PHARMACEUTICALS LTD.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
1. TAH4411 Ondansetron ODF
2. TAH3311 Apixaban Oral Film
3. TAH3341 Apixaban Oral Extend Release Film
4. TAH2211 Buprenorphine/Naloxone Sublingual Film
5. TAH2231 Naloxone Buccal Film
6. TAH9922 Atomoxetine Oral Liquid
7. TAH9901 Methylphenidate Patch
2. TAH3311 Apixaban Oral Film
3. TAH3341 Apixaban Oral Extend Release Film
4. TAH2211 Buprenorphine/Naloxone Sublingual Film
5. TAH2231 Naloxone Buccal Film
6. TAH9922 Atomoxetine Oral Liquid
7. TAH9901 Methylphenidate Patch
The content above was translated by Ai
Founded Year
2010
Unified Business No.
25144594
Status
Active
Number of Employees
10
Total Paid-in
Capital
599,086,150 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2024)、Listing(2026)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
TAHO is a commercial-stage specialty pharma pioneering in oral, transdermal drug delivery systems. Collaborating with our partners across three continents, our pipeline of medicines targets CNS, Geriatric, and Pediatric therapies that provide caregivers with significant treatment options. From concept to commercial, we have several products launched in major markets. Trusted by partner pharma, we devote toward partner value and innovation.
The content above was translated by Ai
